-

Hims & Hers to Announce Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2023 financial results after the market closes on Monday, February 26, 2024. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day.

The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year.

Upcoming Conference Participation

Hims & Hers also announced that members of the company’s management team will be participating in the Morgan Stanley Technology, Media & Telecom Conference on March 6, 2024 in San Francisco. All events will be webcast live and archived on the Hims & Hers investor relations website at https://investors.forhims.com.

About Hims & Hers Health, Inc.

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health.

We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.

For more information, please visit https://investors.hims.com/.

Contacts

Investor Relations

Bill Newby
Investors@forhims.com

Media Relations

Khobi Brooklyn
Press@forhims.com

Hims & Hers Health, Inc.

NYSE:HIMS

Release Versions

Contacts

Investor Relations

Bill Newby
Investors@forhims.com

Media Relations

Khobi Brooklyn
Press@forhims.com

More News From Hims & Hers Health, Inc.

Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of Directors

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, has nominated Kofi Amoo-Gottfried for election as a new director at the company’s 2026 annual shareholder meeting in June. Amoo-Gottfried is a seasoned marketing leader with decades of experience helping global transformative brands change how consumers think about their everyday lives. He served as Chief Marketing Officer at DoorDash and in leadership roles at...

Hims & Hers to Announce First Quarter 2026 Financial Results on May 11, 2026

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report first quarter 2026 financial results after the market closes on Monday, May 11, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referenc...

Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today announced that a broad assortment of Novo Nordisk’s FDA-approved GLP-1 medications are available to eligible customers, including the Wegovy® pill, which is the only FDA-approved GLP-1 weight loss pill.1 As a part of a collaboration with Novo Nordisk, Hims & Hers is making it simpler for customers to access FDA-approved GLP-1 medications which are now available at more affordable prices, with more doses and deli...
Back to Newsroom